The infrastructure moment for AI-driven drug discovery continues to accelerate, with billion-dollar investments flowing into ...

United Therapeutics is a Buy: strong core growth, a goal of $1B quarterly revenue by 2027, plus catalysts ralinepag & Tyvaso ...

Complex chemical processes are essential for making DNA." This long-held assumption in the field of biotechnology has been overturned by a Korean ...

Biotech is having a moment, and the numbers are hard to ignore. The SPDR S&P Biotech ETF (NYSEARCA:XBI) climbed 17.27% over ...

Pharvaris stock jumped early Monday, but closed down, after the FDA agreed to review the company's treatment for a serious ...

A biotech startup and an aerospace startup said their moves to Colorado were based on lifestyle issues and the state’s ...

FHLC is the far cheaper option for long-term investors, charging an expense ratio of just 0.08% compared to BBH's 0.35%. FHLC also pays a higher trailing dividend yield of 1.40%, nearly 0.9 percentage ...

Candel Therapeutics (CADL) shifts to late-stage oncology with CAN-2409 Phase III wins and BLA catalyst. Read here for a ...

After more than a decade of work, University of Minnesota researchers say they have built the first synthetic cell assembled ...

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

Healthcare veteran Dr Douglas Williams discusses the impact of recent political upheaval in the US and the prospect of major ...

The future food industry in the Netherlands is calling on the government to make at least €200M available via the EU's IPCEI mechanism to scale up alternative proteins.